MouCellion Biotech Secures Tens of Millions in Funding to Advance Stem Cell Therapies for Ocular Diseases

Sep 19, 2023 16:01 CST Updated 16:01

Theia Therapeutics

Biopharmaceutical Manufacturer

Recently, focusing on the application of innovationStem CellsTheia Therapeutics, a company specializing in gene therapy for ophthalmic diseases, announced the completion of an angel round of financing worth tens of millions of RMB. This round of financing was led byBeijing Zhongfa Lingchuang·Life Science Park Venture CapitalFund("Beijing Life Science Park Ventures" for short)Exclusive Investment. This round of funding will mainly be used to advance its stem cell therapy pipeline and team building.

On September 18, to accelerate the company's R&D progress, the company recently signed an agreement with Beijing Tongren Hospital affiliated to Capital Medical University and Beijing Ophthalmology Research Institute (hereinafter referred to as "Tongren Hospital and Ophthalmology Research Institute") during the China International Fair for Trade in Services (CIFTIS) regarding the technology transfer cooperation for novel retinal treatments. A strategic cooperation agreement was also signed on the clinical transformation of pluripotent stem cells and the development of new ophthalmic drugs.

Through the signing of this agreement, all parties will further improve the cooperative team, deepen industry-university-research collaboration, and jointly promote the development and application of stem cell-related technologies in the treatment of eye diseases.

Theia Therapeutics Signs Cooperation Agreement with Beijing Tongren Eye Research Institute

Dr. Bowen Deng, Founder and COO of Theia TherapeuticsTheia Therapeutics is a biopharmaceutical company focused on the development of new drugs for degenerative ophthalmic diseases. The company is committed to the research and development of cutting-edge biotechnologies and their application in the treatment of ophthalmic diseases, with multiple pipelines already established, including stem cell therapy and gene therapy. The transfer of related technologies from the Tongren team will significantly enhance Theia Therapeutics' technical capabilities in stem cell regenerative medicine. Theia Therapeutics will also continue to increase its investment in iPSC technology and fully promote the implementation and clinical transformation of the transferred technology. Through a strategic partnership between Theia Therapeutics and the Ophthalmology Research Institute of Tongren Hospital, we will jointly explore solutions to the challenges of applying stem cell technology in ophthalmic disease treatment and advance the clinical application of stem cells.

Theia Therapeutics, founded in 2023, is a biopharmaceutical company focused on the research and development of new drugs for degenerative ophthalmic diseases. By utilizing innovative stem cell and gene therapies to treat ophthalmic conditions, the company aims to address the current lack of effective treatments for degenerative eye diseases such as dry age-related macular degeneration in China. The company has established multiple platform technologies, including in vitro reprogramming and differentiation of induced pluripotent stem cells (iPSC) and AAV vector optimization. Its proprietary eye organoid models and small-to-large animal disease models enable early efficacy and safety evaluation of drug candidates, accelerating the development of its ophthalmology pipeline.